To further support the anti-tumor role of AIM2 in brain cancers, very recently, it was demonstrated that Tumor Treating Fields (TTFields), an approved non-invasive regional anti-mitotic treatment for GBM, generated large cytosolic naked micronuclei clusters in GBM through the focal disruption of the nuclear envelope, thereby recruiting AIM2 and cGAS, leading to the release of pro-inflammatory cytokines and type I IFNs [64]. This evidence concerns the gene AIM2 and brain cancer.